ClinicalTrials.gg
CompletedNCT03375047RESTORE-CFUpdated Feb 9, 2026Results posted

Study to Evaluate the Safety & Tolerability of MRT5005 Administered by Nebulization in Adults With Cystic Fibrosis

A Phase 1/2 interventional study of MRT5005 and Normal saline in Cystic Fibrosis, sponsored by Sanofi. Completed at 16 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-09.

Sponsored by Sanofi · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Enrollment
230th of 517
42 · median 36
Started
2018
with 38 others
Phase 1/2
32 of 717
1 open now
Registered
442nd of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 230th largest by enrollment of the 517 interventional ones that give a count, is one of 39 that started in 2018, is one of 32 in phase 1/2, and was the 442nd registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 200 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 155 Cystic Fibrosis studies recruiting now, 94 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This Phase 1/2, first-in-human study evaluated the safety and tolerability of single and multiple escalating doses of MRT5005 administered by nebulization to the respiratory tract of adult subjects with cystic fibrosis (CF).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

Keywords

  • Cystic Fibrosis
  • CF
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CF as defined by both of the following:

    • Two CF disease-causing cystic fibrosis transmembrane conductance regulator (CFTR) mutations in Class I or II (genotype confirmed at the screening visit).
    • Chronic sinopulmonary disease and/or gastrointestinal/nutritional abnormalities consistent with CF disease.
  • Clinically stable CF disease, as judged by the investigator.
  • (FEV1) ≥50% and ≤90% of the predicted normal for age, gender, and height at screening.
  • Resting oxygen saturation ≥92% on room air (pulse oximetry).

Exclusion criteria

Exclusion Criteria:

  • An acute upper or lower respiratory infection, pulmonary exacerbation, or episode of hemoptysis or change in chronic respiratory medications (including antibiotics) for CF lung disease within 28 days prior to dosing with product on Day 1.
  • Participants were receiving treatment with ivacaftor monotherapy (KALYDECO).
  • Parts A and B only: Were receiving treatment with triple combination therapy (TRIKAFTA).
  • Participants with a Class III, IV, or V CFTR gene mutation in at least 1 allele.
  • Infection with highly virulent bacteria associated with accelerated decline in pulmonary function and/or decreased survival (e.g., Burkholderia cenocepacia, Burkholderia dolosa, Mycobacterium abscessus).

Treatment with ORKAMBI or SYMDEKO was not an exclusion for this study.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Part A - SAD Group 1: MRT5005 8 mg

    Participants received single dose of MRT5005 8 milligrams (mg) by nebulization on Day 1.

    Drug: MRT5005

  • Experimental
    Part A - SAD Group 2: MRT5005 16 mg

    Participants received single dose of MRT5005 16 mg by nebulization on Day 1.

    Drug: MRT5005

  • Experimental
    Part A - SAD Group 3: MRT5005 20 mg

    Participants received single dose of MRT5005 20 mg by nebulization on Day 1.

    Drug: MRT5005

  • Experimental
    Part A - SAD Group 4: MRT5005 24 mg

    Participants received single dose of MRT5005 24 mg by nebulization on Day 1.

    Drug: MRT5005

  • Placebo comparator
    Part A - SAD Groups: Pooled Placebo

    Participants received single dose of placebo (normal saline) by nebulization on Day 1. Data were analyzed as a pooled population for all participants who received placebo in Part A SAD groups and reported in this arm.

    Drug: Normal saline

  • Experimental
    Part B - MAD Group 1: MRT5005 8 mg

    Participants received MRT5005 8 mg once weekly by nebulization for 5 weeks (i.e., on Day 1, Day 8, Day 15, Day 22 and Day 29).

    Drug: MRT5005

  • Experimental
    Part B - MAD Group 2: MRT5005 12 mg

    Participants received MRT5005 12 mg once weekly by nebulization for 5 weeks (i.e., on Day 1, Day 8, Day 15, Day 22 and Day 29).

    Drug: MRT5005

  • Experimental
    Part B - MAD Group 3: MRT5005 16 mg

    Participants received MRT5005 16 mg once weekly by nebulization for 5 weeks (i.e., on Day 1, Day 8, Day 15, Day 22 and Day 29).

    Drug: MRT5005

  • Experimental
    Part B - MAD Group 4: MRT5005 20 mg

    Participants received MRT5005 20 mg once weekly by nebulization for 5 weeks (i.e., on Day 1, Day 8, Day 15, Day 22 and Day 29).

    Drug: MRT5005

  • Placebo comparator
    Part B - MAD Groups: Pooled Placebo

    Participants received placebo (normal saline) once weekly by nebulization for 5 weeks (i.e., on Day 1, Day 8, Day 15, Day 22 and Day 29). Data were analyzed as a pooled population for all participants who received placebo in Part B MAD groups and reported in this arm.

    Drug: Normal saline

  • Experimental
    Part D: MRT5005 4 mg

    Participants received MRT5005 4 mg once daily by nebulization from Day 1 to Day 5.

    Drug: MRT5005

  • Placebo comparator
    Part D: Placebo

    Participants received placebo (normal saline) once daily by nebulization from Day 1 to Day 5.

    Drug: Normal saline

Interventions

  • DrugMRT5005

    Nebulization of MRT5005

  • DrugNormal saline

    Normal Saline for Inhalation

06

What researchers measure

Primary outcomes

  1. Parts A, B and D: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events

    An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily had a causal relationship with the study treatment. A serious adverse event (SAE) was any untoward medical occurrence (whether considered to be related to study treatment or not) that at any dose: resulted in death; or was life-threatening; or required inpatient hospitalization or prolongation of existing hospitalization; or resulted in persistent or significant disability/incapacity; or was a congenital abnormality/birth defect; or was an important medical event. The TEAEs were defined as events that were newly reported or reported to worsen in severity after the start of study treatment up to 48 weeks (end of follow-up period) after the last dose of study treatment administration.

    Time frame: From the first dose of study treatment administration (Day 1) up to 48 weeks (end of the follow-up period) after the last dose of study treatment administration (Part A: Day 337, Part B: Day 365 and Part D: Day 341)

Secondary outcomes

  1. Parts A, B and D: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    Spirometry was performed according to the guidelines published by the American Thoracic Society for standardization of spirometry. The ppFEV1 was assessed during the spirometry testing. For Parts A and B, the baseline value was defined as the average of the results from testing on Day -1 and at pre-dose on Day 1. For Part D, the baseline value was defined as the result from testing pre-dose on Day 1. Here, Baseline= BL, Day= D, pre-dose= PrD, hours post dose= hPD.

    Time frame: Part A:BL, D1(8hPD), D2(24hPD), D3, D8, D15 and D29; Part B:BL, D1(6hPD), D2, D8(PrD and 6hPD), D9, D15(PrD and 6hPD), D16, D22(PrD and 6hPD), D23, D29(PrD and 6hPD), D30, D36, D43 and D57; Part D:BL, D1(2hPD), PrD on D2, D3, D4 and D5, D11, D18 and D32

07

Results

Posted Feb 9, 2026

Participant flow

The study was conducted at 16 active centers. A total of 53 participants were screened from 10 May 2018 to 22 February 2021, of which 11 were screen failures. Screen failures were mainly due to not meeting the eligibility criteria.

Participant flow — Overall Study
MilestonePart A - SAD Group 1: MRT5005 8 mgPart A - SAD Group 2: MRT5005 16 mgPart A - SAD Group 3: MRT5005 20 mgPart A - SAD Group 4: MRT5005 24 mgPart A - SAD Groups: Pooled PlaceboPart B - MAD Group 1: MRT5005 8 mgPart B - MAD Group 2: MRT5005 12 mgPart B - MAD Group 3: MRT5005 16 mgPart B - MAD Group 4: MRT5005 20 mgPart B - MAD Groups: Pooled PlaceboPart D: MRT5005 4 mgPart D: Placebo
Started333343343562
Completed332343333462
Not completed001000010100
Withdrew: Pregnancy001000000000
Withdrew: Adverse event000000010000
Withdrew: Site closure due to coronavirus disease 2019 pandemic000000000100

Outcome measures

PrimaryParts A, B and D: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that did not necessarily had a causal relationship with the study treatment. A serious adverse event (SAE) was any untoward medical occurrence (whether considered to be related to study treatment or not) that at any dose: resulted in death; or was life-threatening; or required inpatient hospitalization or prolongation of existing hospitalization; or resulted in persistent or significant disability/incapacity; or was a congenital abnormality/birth defect; or was an important medical event. The TEAEs were defined as events that were newly reported or reported to worsen in severity after the start of study treatment up to 48 weeks (end of follow-up period) after the last dose of study treatment administration.

Time frame:
From the first dose of study treatment administration (Day 1) up to 48 weeks (end of the follow-up period) after the last dose of study treatment administration (Part A: Day 337, Part B: Day 365 and Part D: Day 341)
Reported as:
Count of participants · Participants
Parts A, B and D: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events
ParticipantsPart A - SAD Group 1: MRT5005 8 mgPart A - SAD Group 2: MRT5005 16 mgPart A - SAD Group 3: MRT5005 20 mgPart A - SAD Group 4: MRT5005 24 mgPart A - SAD Groups: Pooled PlaceboPart B - MAD Group 1: MRT5005 8 mgPart B - MAD Group 2: MRT5005 12 mgPart B - MAD Group 3: MRT5005 16 mgPart B - MAD Group 4: MRT5005 20 mgPart B - MAD Groups: Pooled PlaceboPart D: MRT5005 4 mgPart D: Placebo
Any TEAE333343343562
Any Serious TEAE001131102211
SecondaryParts A, B and D: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

Spirometry was performed according to the guidelines published by the American Thoracic Society for standardization of spirometry. The ppFEV1 was assessed during the spirometry testing. For Parts A and B, the baseline value was defined as the average of the results from testing on Day -1 and at pre-dose on Day 1. For Part D, the baseline value was defined as the result from testing pre-dose on Day 1. Here, Baseline= BL, Day= D, pre-dose= PrD, hours post dose= hPD.

Time frame:
Part A:BL, D1(8hPD), D2(24hPD), D3, D8, D15 and D29; Part B:BL, D1(6hPD), D2, D8(PrD and 6hPD), D9, D15(PrD and 6hPD), D16, D22(PrD and 6hPD), D23, D29(PrD and 6hPD), D30, D36, D43 and D57; Part D:BL, D1(2hPD), PrD on D2, D3, D4 and D5, D11, D18 and D32
Reported as:
Mean · percent predicted FEV1
Parts A, B and D: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percent predicted FEV1Part A - SAD Group 1: MRT5005 8 mgPart A - SAD Group 2: MRT5005 16 mgPart A - SAD Group 3: MRT5005 20 mgPart A - SAD Group 4: MRT5005 24 mgPart A - SAD Groups: Pooled PlaceboPart B - MAD Group 1: MRT5005 8 mgPart B - MAD Group 2: MRT5005 12 mgPart B - MAD Group 3: MRT5005 16 mgPart B - MAD Group 4: MRT5005 20 mgPart B - MAD Groups: Pooled PlaceboPart D: MRT5005 4 mgPart D: Placebo
Day 1: 2 hours post-dose——————————5.1117 ± 3.75481-2.4150 ± 1.23744
Day 1: 6 hours post-dose—————-2.7017 ± 3.37188-0.3417 ± 2.17959-0.0062 ± 2.66067-1.9533 ± 8.525381.8400 ± 4.62365——
Day 1: 8 hours post-dose3.6550 ± 0.942307.2233 ± 7.290171.1067 ± 1.912472.4525 ± 0.441941.1088 ± 3.58541———————
Day 2: Pre-dose——————————3.7300 ± 6.24287-0.1600 ± 4.11536
Day 22.7750 ± 1.8436911.2100 ± 10.325094.0967 ± 4.745048.6233 ± 11.208690.1863 ± 2.04118-2.2383 ± 2.84509-0.2317 ± 0.754661.7013 ± 2.566122.0067 ± 2.487022.2360 ± 4.56081——
Day 3: Pre-dose——————————2.7583 ± 7.60588-1.8350 ± 0.65761
Day 33.4183 ± 2.2915211.3767 ± 5.145162.3700 ± 5.722786.5800 ± 4.81868-1.6687 ± 3.21471———————
Day 4: Pre-dose——————————1.8367 ± 7.007832.0050 ± 3.38704
Day 5: Pre-dose——————————2.7833 ± 5.625750.9100 ± 4.53963
Day 8: Pre-dose—————-0.9883 ± 0.65929-0.8617 ± 2.502501.9033 ± 3.87243-5.0133 ± 6.390824.8563 ± 3.87653——
Day 8: 6 hours post-dose—————-3.0250 ± 2.665400.7650 ± 4.124272.6400 ± 3.60712-5.2500 ± 13.558091.7488 ± 4.61824——
Day 8-1.2350 ± 3.028429.1867 ± 1.783400.8533 ± 0.961442.2867 ± 3.15587-0.9512 ± 3.31965———————
Day 9—————-0.2550 ± 3.32058-1.9250 ± 1.444390.9800 ± 2.77307-0.3067 ± 3.839392.4963 ± 3.58692——
Day 11——————————1.0567 ± 2.53699-0.8450 ± 3.14663
Day 15: Pre-dose—————1.4783 ± 4.88812-2.2750 ± 3.359293.2767 ± 2.85037-7.0867 ± 3.291600.2438 ± 4.78050——
Day 15: 6 hours post-dose—————-1.9083 ± 4.30519-0.8350 ± 0.482103.5100 ± 2.36540-3.0233 ± 10.090213.6763 ± 2.82176——
Day 15-0.2383 ± 3.634705.5633 ± 1.21378-2.3233 ± 1.802920.4833 ± 5.256630.5763 ± 1.57608———————
Day 16—————-2.6017 ± 3.59609-4.4217 ± 0.243221.6800 ± 1.39796-3.9033 ± 6.247932.5388 ± 5.43594——
Day 18——————————0.1600 ± 1.78332-1.3700 ± 0.77782
Day 22: Pre-dose—————-3.4417 ± 0.79907-2.5317 ± 3.124071.0433 ± 2.61190-3.5567 ± 3.441811.6863 ± 6.44122——
Day 22: 6 hours post-dose—————-4.4150 ± 1.30844-3.1183 ± 2.603351.4033 ± 2.70263-3.2933 ± 8.336134.9788 ± 8.56683——
Day 23—————-2.5650 ± 2.27414-3.5550 ± 1.421632.6233 ± 5.05601-3.1900 ± 6.423240.7463 ± 8.20475——
Day 29: Pre-dose—————-4.1350 ± 1.25896-2.9725 ± 3.425930.1667 ± 1.82582-5.7133 ± 2.390362.9863 ± 9.33491——
Day 29: 6 hours post-dose—————-4.7350 ± 0.703260.3125 ± 0.060100.8467 ± 1.795280.0567 ± 11.032002.7563 ± 4.51659——
Day 293.0983 ± 4.901884.6633 ± 4.654452.5133 ± 5.06806-5.2633 ± 13.066480.7517 ± 4.27498———————
Day 30—————-3.2717 ± 4.61490-4.7375 ± 3.984554.8000 ± 5.947781.1667 ± 8.987560.9888 ± 7.33033——
Day 32——————————4.8550 ± 6.05264-0.1150 ± 4.49013
Day 36—————-0.9383 ± 2.30022-2.2975 ± 2.85318-0.7733 ± 5.20926-3.5333 ± 8.930394.8463 ± 8.26378——
Day 43—————-3.2550 ± 0.69262-0.0050-2.0367 ± 6.75614-3.1533 ± 3.508105.1363 ± 7.51406——
Day 57—————-5.5517 ± 4.389181.07501.9500 ± 1.02103-7.1667 ± 9.319290.4288 ± 5.91134——

Adverse events

Collected over Serious adverse events (AEs), other AEs and all-cause mortality (deaths) were collected from the first dose of study treatment administration (Day 1) up to 48 weeks (end of the follow-up period) after the last dose of study treatment administration (Part A: Day 337, Part B: Day 365 and Part D: Day 341). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A - SAD Group1: MRT5005 8 mg0/3 (0%)0/3 (0%)3/3 (100%)
Part A - SAD Group 2: MRT5005 16 mg0/3 (0%)0/3 (0%)3/3 (100%)
Part A - SAD Group 3: MRT5005 20 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part A - SAD Group 4: MRT5005 24 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part A - SAD Groups: Pooled Placebo0/4 (0%)3/4 (75%)4/4 (100%)
Part B - MAD Group 1: MRT5005 8 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part B - MAD Group 2: MRT5005 12 mg0/3 (0%)1/3 (33.3%)3/3 (100%)
Part B - MAD Group 3: MRT5005 16 mg0/4 (0%)0/4 (0%)4/4 (100%)
Part B - MAD Group 3: MRT5005 20 mg0/3 (0%)2/3 (66.7%)3/3 (100%)
Part B - MAD Groups: Pooled Placebo0/5 (0%)2/5 (40%)5/5 (100%)
Part D: MRT5005 4 mg0/6 (0%)1/6 (16.7%)6/6 (100%)
Part D: Placebo0/2 (0%)1/2 (50%)2/2 (100%)
Most frequent serious events
Most frequent serious events
EventPart A - SAD Group1: MRT5005 8 mgPart A - SAD Group 2: MRT5005 16 mgPart A - SAD Group 3: MRT5005 20 mgPart A - SAD Group 4: MRT5005 24 mgPart A - SAD Groups: Pooled PlaceboPart B - MAD Group 1: MRT5005 8 mgPart B - MAD Group 2: MRT5005 12 mgPart B - MAD Group 3: MRT5005 16 mgPart B - MAD Group 3: MRT5005 20 mgPart B - MAD Groups: Pooled PlaceboPart D: MRT5005 4 mgPart D: Placebo
Infective Pulmonary Exacerbation Of Cystic FibrosisInfections and infestations0/30/31/31/32/41/30/30/41/32/51/61/2
Small Intestinal ObstructionGastrointestinal disorders0/30/30/30/30/40/30/30/41/30/50/60/2
Calculus UrinaryRenal and urinary disorders0/30/30/30/30/40/30/30/41/30/50/60/2
Femoral Neck FractureInjury, poisoning and procedural complications0/30/30/30/30/40/31/30/40/30/50/60/2
Cholecystitis AcuteHepatobiliary disorders0/30/30/30/31/40/30/30/40/30/50/60/2
Anaphylactic ReactionImmune system disorders0/30/30/30/30/40/30/30/40/30/51/60/2
Most frequent other events
Showing 10 of 178
Most frequent other events
EventPart A - SAD Group1: MRT5005 8 mgPart A - SAD Group 2: MRT5005 16 mgPart A - SAD Group 3: MRT5005 20 mgPart A - SAD Group 4: MRT5005 24 mgPart A - SAD Groups: Pooled PlaceboPart B - MAD Group 1: MRT5005 8 mgPart B - MAD Group 2: MRT5005 12 mgPart B - MAD Group 3: MRT5005 16 mgPart B - MAD Group 3: MRT5005 20 mgPart B - MAD Groups: Pooled PlaceboPart D: MRT5005 4 mgPart D: Placebo
Infective Pulmonary Exacerbation Of Cystic FibrosisInfections and infestations3/32/33/33/33/43/30/32/40/32/53/61/2
HeadacheNervous system disorders2/33/31/33/31/41/31/31/43/31/52/60/2
CoughRespiratory, thoracic and mediastinal disorders3/32/31/33/30/43/32/34/41/33/52/62/2
VomitingGastrointestinal disorders0/30/30/33/30/40/31/31/41/30/50/60/2
PyrexiaGeneral disorders1/32/30/33/30/40/31/33/42/30/50/60/2
HaemoptysisRespiratory, thoracic and mediastinal disorders1/30/32/31/33/40/30/32/41/32/51/60/2
ChillsGeneral disorders1/31/30/32/30/41/31/33/42/30/51/60/2
SinusitisInfections and infestations0/32/31/31/31/41/30/31/40/32/50/61/2
Upper Respiratory Tract InfectionInfections and infestations0/31/31/31/31/41/30/30/42/30/51/61/2
DizzinessNervous system disorders1/31/30/31/31/42/30/30/40/32/51/60/2

Baseline characteristics

The Safety analysis set included all randomized participants who received study treatment.

Age, Categorical
Age, Categorical(Participants)Part A - SAD Group 1: MRT5005 8 mgPart A - SAD Group 2: MRT5005 16 mgPart A - SAD Group 3: MRT5005 20 mgPart A - SAD Group 4: MRT5005 24 mgPart A - SAD Groups: Pooled PlaceboPart B - MAD Group 1: MRT5005 8 mgPart B - MAD Group 2: MRT5005 12 mgPart B - MAD Group 3: MRT5005 16 mgPart B - MAD Group 4: MRT5005 20 mgPart B - MAD Groups: Pooled PlaceboPart D: MRT5005 4 mgPart D: PlaceboTotal
<=18 years0000000000000
Between 18 and 65 years33334334346241
>=65 years0000000001001
Sex: Female, Male
Sex: Female, Male(Participants)Part A - SAD Group 1: MRT5005 8 mgPart A - SAD Group 2: MRT5005 16 mgPart A - SAD Group 3: MRT5005 20 mgPart A - SAD Group 4: MRT5005 24 mgPart A - SAD Groups: Pooled PlaceboPart B - MAD Group 1: MRT5005 8 mgPart B - MAD Group 2: MRT5005 12 mgPart B - MAD Group 3: MRT5005 16 mgPart B - MAD Group 4: MRT5005 20 mgPart B - MAD Groups: Pooled PlaceboPart D: MRT5005 4 mgPart D: PlaceboTotal
Female01212313135123
Male32122021221119
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A - SAD Group 1: MRT5005 8 mgPart A - SAD Group 2: MRT5005 16 mgPart A - SAD Group 3: MRT5005 20 mgPart A - SAD Group 4: MRT5005 24 mgPart A - SAD Groups: Pooled PlaceboPart B - MAD Group 1: MRT5005 8 mgPart B - MAD Group 2: MRT5005 12 mgPart B - MAD Group 3: MRT5005 16 mgPart B - MAD Group 4: MRT5005 20 mgPart B - MAD Groups: Pooled PlaceboPart D: MRT5005 4 mgPart D: PlaceboTotal
White33333334356241
Black or African American0000100000001
08

Study locations

16 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Indiana
    Indianapolis, Indiana 46202, United States
  • Maine Medical Center
    Portland, Maine 04102, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267, United States
  • University Hospitals
    Cleveland, Ohio 44106, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Oregon Health and Sciences University
    Portland, Oregon 97239, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • New Orleans Center for Clinical Research
    Knoxville, Tennessee 37920, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
09

References and documents

Publications

  • Miah KM, Hyde SC, Gill DR. Emerging gene therapies for cystic fibrosis. Expert Rev Respir Med. 2019 Aug;13(8):709-725. doi: 10.1080/17476348.2019.1634547. Epub 2019 Jun 27. PubMed 31215818 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2018 to primary completion in Mar 2022, 46 months.

Results were first posted in Feb 2026, 3 years 10 months after primary completion.

Of 26 phase 1/2 interventional studies under Cystic Fibrosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 46 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2017
First posted
Dec 15, 2017
StartActual
May 10, 2018
Primary completionActual
Mar 15, 2022
CompletionActual
Mar 15, 2022
Results first posted
Feb 9, 2026
Last update
Feb 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03375047
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Dec 15, 2017
Start date
May 10, 2018
Primary completion
Mar 15, 2022
Completion
Mar 15, 2022
Results posted
Feb 9, 2026
Last update
Feb 9, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion